Literature DB >> 16419966

Osteoclastogenesis in the nonadherent cell population of human bone marrow is inhibited by rhBMP-2 alone or together with rhVEGF.

Chao Wan1, Qiling He, Gang Li.   

Abstract

During bone development and repair, angiogenesis, osteogenesis, and bone remodeling are closely associated processes that share some common mediators. In the present study nonadherent human bone marrow mononuclear cells under the induction of sRANKL and M-CSF, differentiated into osteoclasts with TRAP-positive staining, VNR expression, and Ca-P resorptive activity. The effects of various combinations of rhBMP-2 (0, 3, 30, and 300 ng/mL) and rhVEGF (0 and 25 ng/mL) on osteoclastogenesis potentials were examined in this experimental system. The percentages of TRAP-positive multiple nucleated cells represent osteoclast differentiation potential, and the percentages of resorptive areas in the Ca-P coated plates resemble osteoclast resorption capability. The presence of rhBMP-2 at 30 and 300 ng/mL showed inhibitory effects on osteoclast differentiation and their resorptive capability in the human osteoclast culture system. rhVEGF (25 ng/mL) enhanced the resorptive function of osteoclast whenever it was used alone or combined with 3 ng/mL rhBMP-2. However, rhVEGF-induced resorptive function was inhibited by 30 ng/mL and 300 ng/mL rhBMP-2 in a dose-dependent manner. Statistical analysis demonstrated that an interactive effect exists between rhBMP-2 and rhVEGF on human osteoclastogenesis. These findings suggested that an interactive regulation may exist between BMPs and VEGF signaling pathways during osteoclastogenesis; exact mechanisms are yet to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16419966     DOI: 10.1002/jor.20010

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  4 in total

Review 1.  Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence.

Authors:  P V Giannoudis; N K Kanakaris; T A Einhorn
Journal:  Osteoporos Int       Date:  2007-08-12       Impact factor: 4.507

2.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

3.  Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures.

Authors:  Katherine A Blackwell; Peter Hortschansky; Srdan Sanovic; Shilpa Choudhary; Lawrence G Raisz; Carol C Pilbeam
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-09-08       Impact factor: 3.072

Review 4.  The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective.

Authors:  Franziska Lademann; Lorenz C Hofbauer; Martina Rauner
Journal:  Front Cell Dev Biol       Date:  2020-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.